News

Patients receiving csDMARDs had a significant reduction (40%) in non-serious infection (NSI) risk when compared with biologics.

Poorer results were associated with lower socioeconomic status (SES) and not being able to access telehealth, which emphasizes the need for access to healthcare and attention to vulnerable populations, such as those with rheumatic diseases, during the pandemic.

While men with inflammatory arthritis drink significantly more alcohol and have less severe disease activity, alcohol is not linked to disease remission.

A UK-based study indicated that patients with RA were more likely to have severe COVID-19 outcomes, including death. However, patients with gout did not appear to have an increased risk.

Rheumatoid arthritis increases cardiovascular risk and the risk of heart attack, but by how much and what impact does treatment have on that risk? Test your knowledge in this quiz.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 30, 2021.

The SPIN-CHAT Program was developed by investigators in order to help participants deal with isolation and learn better mental health coping mechanisms.

A study characterizing frailty in patients with rheumatoid arthritis finds psychosocial factors could be more important determinants than aging.

“In this large, multiethnic, single-center, cohort study of children born to anti-Ro antibody positive mothers, the child’s ethnicity was not associated with NLE risk, nor specific NLE manifestations,” stated investigators.

Investigators observed that patients treated with secukinumab were more likely to achieve Psoriasis Area Severity Index (PASI) 75/90/100 responses and Investigator’s Global Assessment (IGA) improvement at 52 weeks than those administered usetkinumab, regardless of their psoriatic arthritis (PsA) status.

“The sustained benefits for patients with active psoriatic arthritis across multiple domains indicate that guselkumab may offer a novel mechanism by which to provide extended improvements in the diverse manifestations of psoriatic arthritis,” Laura Coates, PhD, and team concluded.

A comparison of pooled phase 3 data showed patients treated with the IL-17A inhibitor fared better than those on ustekinumab, without influence from their PsA status.

A post-hoc analysis shows that the human monoclonal antibody was linked to sustained improvements according to different disease measurements through week 52.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 23, 2021.

Mindfulness interventions teach and promote the use of psychological skills to improve quality of life among individuals with chronic conditions like rheumatic disease. These interventions largely act by reducing pain-related activation in the sensory cortex and increasing activity in the cingulate cortex, the area of the brain responsible for learning, memory, and processing bodily sensations, like pain.

Investigators discovered that women with axial spondyloarthritis (axSpA) have an overall higher disease burden and more peripheral manifestations when compared with men. They further theorized that awareness of these differences and the way the condition presents differently in both sexes may be used to more easily identify axSpA and improve disease management.

Patients with rheumatoid arthritis (RA) have a poorer prognosis after myocardial infarction (MI) than patients without RA, and longer RA disease duration and glucocorticoid use before MI are associated with higher mortality and recurrent MI.

A majority of studies reported a worsening of disease activity post-delivery.

While further studies are needed, the results indicate that resolving the SDoH issues, via programs like the iCMP, may decrease healthcare costs while equalizing care and outcomes for both patients with SLE and those with complex chronic conditions in general.

Long-term administration of rituximab may be associated with more severe COVID-19 outcomes, including intensive care unit (ICU) admission or death, especially for those with other comorbidities.

A treat-to-target strategy is recommended by the American College of Rheumatology for managing rheumatoid arthritis patients over a non-targeted approach. Test your knowledge of the rationale for treat-to target and how it should be implemented in our quiz.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 16, 2021.

A new study finds atorvastatin does not have significant effect versus placebo on treating symptomatic knee osteoarthritis, including cartilage loss.

Patients with psoriatic arthritis (PsA) treated with guselkumab resulted in higher percentages of resolved enthesitis by Week 24 and maintained those results through 1 year when compared with a placebo.

While incidence rates remained stable throughout the study period, incidence rates in females increased 3% per year between 2000 and 2017. The increase was seen primarily in women 40-49 and 50-59.

A study finds low risk of malignancy from secukinumab treatment for psoriasis, psoriatic arthritis and ankylosing spondylitis patients, despite limited data.

In this systematic review and meta-analysis, investigators aimed to evaluate the clinical safety of total glucosides of paeony (TGP) adjuvant therapy in the treatment of rheumatoid arthritis (RA).

A recent study finds increasing number of women with PsA, but an overall stable incidence of disease compared to previous studies in same population.

Study participants who received combined video and booklet education were more effective in changing self-care behaviors. The education tools additionally provided greater advantages for Spanish-speaking and less-educated patients.